国药集团一致药业股份有限公司 2015 年年度报告摘要
Stock Code: 000028/200028 Notice No.:
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Annual Report 2015
I. Important Notice
The summary is abstract from full-text of annual report, for more details of operating results, financial condition and future
development plan of the Company; investors should found in the full-text of annual report that published on media appointed by
CSRC.
Objection statement of directors, supervisors and senior executives
Name Position Content and reason
Statement
Other directors attending the Meeting for annual report deliberation except for the followed
Name of director absent Title for absent director Reasons for absent Attorney
Prompt of non-standard audit opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting
period
√Applicable □Not applicable
Whether has capitalizing of common reserves carried out
□Yes √ No
The profit distribution plan that deliberated and approved by the Board is: based on total stock issued 362, 631, 943 shares,
distributed 3.00 Yuan (tax included) bonus in cash for every 10-share hold by all shareholders, 0 shares bonus issued (tax included)
and no capitalizing of common reserves carried out.
Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
Company Profile
Short form of the stock Sinopharm Accord, Accord B Stock code 000028、200028
Stock exchange for listing Shenzhen Stock Exchange
Person/Way to contact Secretary of the Board Rep. of security affairs
Name Chen Changbing
Accord Pharm. Bldg., No. 15, Ba Gua Si
Office add. Road, Futian District, Shenzhen, Guangdong
Province
Fax. +(86)755 25195435
Tel. +(86)755 25875195
0028@szaccord.com.cn；
gyyz0028@sinopharm.com
II. Main business or product introduction in the reporting period
The main business of China National Accord Medicines includes pharmaceutical
distribution and pharmaceutical industry; the company adheres to the joint
development of technical research and development, industrial manufacturing and
marketing and trade, and commits to become a provider for pharmaceutical and
1
国药集团一致药业股份有限公司 2015 年年度报告摘要
healthcare products and services with international competitiveness.
(I) In the pharmaceutical distribution field, the company continues to integrate the
distribution and logistics business, deeply penetrates into the end markets, improves
the multistep distribution network, creates intelligent supply chain, and devotes to
become a provider for pharmaceutical and healthcare products and services with the
strongest influence, the highest share, the most complete variety, the best service, and
the fastest delivery in south district of China.
(II) In the pharmaceutical industry field, the company continues to integrate the
research & development and marketing and take the technological innovation as a
guide so as to become a provider for pharmaceutical and healthcare products and
services with quality leadership, core competitiveness, transverse diversification,
complete lengthways industry chain and brand influence in the domestic and
international markets
III. Main accounting data and financial indexes
1. Main accounting data and financial indexes for recently three years
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□Yes √ No
In RMB
Changes over last
2015 2014 2013
year
Operating income 25,993,139,277.84 23,954,331,028.05 8.51% 21,199,466,399.21
Net profit attributable to
shareholders of the listed 761,312,261.06 652,497,176.03 16.68% 520,488,198.80
company
Net profit attributable to
shareholders of the listed
715,212,681.54 611,245,652.69 17.01% 505,828,794.23
company after deducting
non-recurring gains and losses
Net cash flow arising from
1,047,979,102.98 -796,697,032.43 231.54% 465,028,099.83
operating activities
Basic earnings per share
2.10 1.90 10.53% 1.81
(RMB/Share)
Diluted earnings per share
2.10 1.90 10.53% 1.81
(RMB/Share)
Weighted average ROE 14.94% 16.41% -1.47% 26.00%
Changes over end of
End of 2015 End of 2014 End of 2013
last year
Total assets 13,218,349,735.31 12,828,941,540.90 3.04% 11,057,896,941.31
Net assets attributable to
5,453,393,694.55 4,764,607,822.09 14.46% 2,244,757,658.03
shareholder of listed company
2. Quarterly main financial index
In RMB
2
国药集团一致药业股份有限公司 2015 年年度报告摘要
First quarter Second quarter Third quarter Fourth quarter
Operating income 6,261,714,700.23 6,552,088,466.54 6,866,003,376.77 6,313,332,734.30
Net profit attributable to
shareholders of the listed 197,026,237.82 190,293,014.51 186,753,078.44 187,239,930.29
company
Net profit attributable to
shareholders of the listed
192,315,542.07 181,343,611.72 183,019,662.66 158,533,865.09
company after deducting
non-recurring gains and losses
Net cash flow arising from
182,179,606.70 266,059,972.13 -40,080,428.91 639,819,953.06
operating activities
Whether there are significant differences between the above-mentioned financial index or its total number and the relevant financial
index disclosed in the company’s quarterly report and semi-annual report
□Yes √ No
IV. Shares and shareholders
1. Particulars about common stock shareholders, preference shareholders with voting rights recovered and
top ten shareholders
In Share
Total preference
Total common Total preference
Total common shareholders with
stock shareholders
stock voting rights
shareholders at with voting
shareholders in 14,861 14,861 0 recovered at end of 0
end of last month rights recovered
reporting last month before
before annual at end of
period-end annual report
report disclosed reporting period
disclosed
Top ten shareholders
Amount of Number of shares
Full name of Nature of Proportion of pledged/frozen
Amount of restricted shares held
Shareholders shareholder shares held shares held
State of share Amount
Sinopharm
State-owned
Holding Co., 51.00% 184,942,291 74,482,543
Corporation
Ltd.
National Domestic
Council for non
2.29% 8,300,000
Social Security state-owned
Fund-116 Corporation
Domestic
China Securities
non
Finance Co., 2.12% 7,704,972
state-owned
Ltd.
Corporation
National Domestic
Council for non
2.01% 7,298,555
Social Security state-owned
Fund-106 Corporation
HTHK/CMG
FSGUFP-CMG
Foreign
FIRST STATE 1.94% 7,032,720
Corporation
CHINA
GROWTH FD
VALUE
PARTNERS Foreign
1.58% 5,737,088
CLASSIC Corporation
FUND
CITIC Domestic 1.38% 5,009,037
Securities Co., non
3
国药集团一致药业股份有限公司 2015 年年度报告摘要
Ltd. state-owned
Corporation
New China Life
Insurance Co.,
Domestic
Ltd. – Bonus –
non
Individual 1.16% 4,199,772
state-owned
bonuses -
Corporation
-018L-FH002
Shen
Central Huijin State-owned
1.05% 3,804,400
Investment Ltd. Corporation
China Life
Insurance Co.,
Ltd. – tradition Domestic
–general non
1.03% 3,750,090
insurance state-owned
products Corporation
-005L-CT001
Shen
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the among the other tradable shareholders regulated by the Management Measure of Information
aforesaid shareholders Disclosure on Change of Shareholding for Listed Companies.
2. Total preferred stock shareholders of the Company and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
The Company had no shareholders with preferred stock held in the reporting.
4
国药集团一致药业股份有限公司 2015 年年度报告摘要
3. Property right and controlling relationships between the actual controllers of the Company and the
Company is as follows:
The State-owned Assets Supervision & Administration Commission of the State Council
100%
National Council for Social
China National Pharmaceutical Security Fund &public
Shanghai Fosun Pharmaceutical Group Corporation shareholder
(Group) Co., Ltd.
49% 51% 43.11%
Sinopharm Industry
Investment Co., Ltd. 0.10%
56.79%
Sinopharm Holding Co., Ltd.
51%
China National Accord Medicines Corporation Ltd.
V. Discussion and analysis by the Management Team
1. Introduction of operation in the reporting period
2015 is the last year of "the 12th Five-Year Plan". In the past year, the company has
always faced the challenges beyond imagination and changeable environment, the
pressure of macro economy downturn was increasing, the financial field was
unordered and turbulent, and the changes of various policies including clinical drug
verification, new versions of GMP / pharmacopeia, unannounced inspection,
electronic supervision code, and decrease of bid price make us have no time for them.
In face of the harsh environment and unfavorable situation, the company has ensured
the performance growth, the managers at all levels and staff have assumed
5
国药集团一致药业股份有限公司 2015 年年度报告摘要
responsibilities and responded actively, the company’s annual sales has exceeded 30
billion yuan in the joint efforts of all staff, the net profit has continued a steady and
rapid growth, and the cash flow has got the best level. At the same time, in the
company’s published major asset restructuring programs, the company has been
determined to engage in the distribution business in Guangdong and Guangxi, create
the unique national retail platform of China National Pharmaceutical Group, and
participate in pharmaceutical industry. All these depend on the support of
shareholders, the endeavor of team, and the hard work of all staff; our market position
has established the company's scale, and our efforts have supported our values.
In 2015, the Company realized operating income of RMB 25.993 billion,
representing a year-on-year increase of 8.51%; net profit attributable to shareholders
of listed company of RMB 761 million, representing a year-on-year increase of
16.68%. The Company has continued to keep growth.
As for distribution segment, operating income was RMB 24.325 billion, representing
a year-on-year increase of 9.10%; net profit of RMB 439 million, representing a
year-on-year increase of 24.16%.
As for pharmaceutical segment, operating income was RMB 1.677 billion,
representing a year-on-year decrease of 0.30%; net profit of RMB 254 million,
representing a year-on-year increase of 12.51%.
The major works done throughout the year:
1. Innovate management ideas, promote quality and efficiency
2. Optimize industry structure, and product mix becomes more reasonable
3. Speed up the distribution network sink to form complete network coverage
4. New distribution business has significantly enhanced and formed new scale
contributions
5. Promote the construction of industrial base and expand the space for
industrial development
6. Establish an international brand, and strengthen the competitive advantages
of domestic species
7. Focus on the strategy of large variety, and drive the industrial transformation
8. Major asset restructuring of the Company
More details can be seen in the full text of annual report of “I-Introduction” in
“VI-Discussion and Analysis by the Management Team”
2. Whether the main business had major change in the reporting period
□ Yes √ No
3. About the industries, products, or regions accounting for over 10% of the company’s operating income or
operating profit
□ Applicable √ Not applicable
4. Whether the characteristics of management seasonal or cyclical need special attention
□ Yes √ No
6
国药集团一致药业股份有限公司 2015 年年度报告摘要
5. In the reporting period, note of major changes in operating income, operating cost, total net profit
attributable to common stock shareholders of listed company or composing the previous reporting period
□ Applicable √ Not applicable
6. Particular about suspended and delisting
□ Applicable √ Not applicable
VI. Relevant items involving financial report
1. Particulars about the changes in aspect of accounting policy, estimates and calculation method compared
with the financial report of last year
□ Applicable √ Not applicable
No particulars about the changes in aspect of accounting policy, estimates or calculation method in Period.
2. Major accounting errors within reporting period that needs retrospective restatement
□ Applicable √ Not applicable
No major accounting errors within reporting period that needs retrospective restatement for the Company in the period.
3. Compare with last year’s financial report; explain changes in consolidation statement’s scope
√Applicable □Not applicable
Enterprise newly established: Sinopharm Holding Guangzhou Medical Management Co., Ltd.
4. Explanation on “Qualified Opinion” from the Certified Public Accountants in the report period by the
Board of Directors and Supervisory Committee
□ Applicable √ Not applicable
7
首页
微信公众号
证券之星APP
